Universal Ibogaine Stock Performance
| IBOGF Stock | USD 0.01 0.0009 17.65% |
On a scale of 0 to 100, Universal Ibogaine holds a performance score of 3. The entity has a beta of -0.19, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Universal Ibogaine are expected to decrease at a much lower rate. During the bear market, Universal Ibogaine is likely to outperform the market. Please check Universal Ibogaine's potential upside, daily balance of power, and the relationship between the treynor ratio and expected short fall , to make a quick decision on whether Universal Ibogaine's existing price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Universal Ibogaine are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile technical and fundamental indicators, Universal Ibogaine reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.2 M | |
| Total Cashflows From Investing Activities | -2.1 M | |
| Free Cash Flow | -4.4 M |
Universal |
Universal Ibogaine Relative Risk vs. Return Landscape
If you would invest 1.10 in Universal Ibogaine on September 26, 2025 and sell it today you would lose (0.50) from holding Universal Ibogaine or give up 45.45% of portfolio value over 90 days. Universal Ibogaine is currently producing 0.7869% returns and takes up 18.9771% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Universal, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Universal Ibogaine Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Universal Ibogaine's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Universal Ibogaine, and traders can use it to determine the average amount a Universal Ibogaine's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0415
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IBOGF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Universal Ibogaine is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Universal Ibogaine by adding it to a well-diversified portfolio.
Universal Ibogaine Fundamentals Growth
Universal Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Universal Ibogaine, and Universal Ibogaine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Universal Pink Sheet performance.
| Return On Equity | -1.06 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (4.29) % | |||
| Current Valuation | 4.25 M | |||
| Shares Outstanding | 191.14 M | |||
| Price To Book | 1.25 X | |||
| Price To Sales | 3.67 X | |||
| Revenue | 1.07 M | |||
| EBITDA | (10.16 M) | |||
| Cash And Equivalents | 1.95 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.74 M | |||
| Debt To Equity | 0.24 % | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (4.33 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 6.32 M | |||
About Universal Ibogaine Performance
By analyzing Universal Ibogaine's fundamental ratios, stakeholders can gain valuable insights into Universal Ibogaine's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Universal Ibogaine has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Universal Ibogaine has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. It undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine is traded on OTC Exchange in the United States.Things to note about Universal Ibogaine performance evaluation
Checking the ongoing alerts about Universal Ibogaine for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Universal Ibogaine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Universal Ibogaine is way too risky over 90 days horizon | |
| Universal Ibogaine has some characteristics of a very speculative penny stock | |
| Universal Ibogaine appears to be risky and price may revert if volatility continues | |
| Universal Ibogaine has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 1.07 M. Net Loss for the year was (10.5 M) with profit before overhead, payroll, taxes, and interest of 497.15 K. | |
| Universal Ibogaine has accumulated about 1.95 M in cash with (4.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Universal Ibogaine's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Universal Ibogaine's stock is overvalued or undervalued compared to its peers.
- Examining Universal Ibogaine's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Universal Ibogaine's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Universal Ibogaine's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Universal Ibogaine's pink sheet. These opinions can provide insight into Universal Ibogaine's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Universal Pink Sheet analysis
When running Universal Ibogaine's price analysis, check to measure Universal Ibogaine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Universal Ibogaine is operating at the current time. Most of Universal Ibogaine's value examination focuses on studying past and present price action to predict the probability of Universal Ibogaine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Universal Ibogaine's price. Additionally, you may evaluate how the addition of Universal Ibogaine to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |